Rochester NY, 16 February 17, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare and haircare solutions, proudly welcomes to the company Dr. Carla Mazzeo PhD, a global authority in exosome research who has more than 30 publications. She will spearhead company advancements in exosome-based skin, scalp, and hair care. Dr. Mazzeo, a leader in exosome research since 2004, was a Director and Senior Scientific Researcher at Boston University and Boston University Medical Center. She brings unparalleled expertise to enhance RESILIÉLLE’s commitment to excellence. [Read more…]
Leveraging Exosomes as Biomarkers for Cancer and Beyond
In recent years, exosomes have emerged as promising and sensitive cancer biomarkers for use in disease diagnosis. Exosomes released from cancer cells after entering the circulation are transported in biological fluids along with their functional cargoes. Profiling the nucleic acids of exosomes derived from cancer cells by ultrasensitive next-generation sequencing and proteins by large-scale high-throughput proteomics can help us in early cancer detection, therapeutic stratification, and monitoring patient-specific responses to various cancer therapies. [Read more…]
RESILIÉLLE COSMETICS LLC Unveils Exosome Results of First-Ever 100-Person Trial on Age Zero Exosome Cosmetic Serum Applied Topically Post Microneedling
Eight Medical Spas Participate in Nationwide Pioneering Study
Rochester NY, February 13, 2024 – RESILIÉLLETM Cosmetics LLC, a leader in innovative skincare solutions, proudly announces the successful completion of the world’s first 100-person microneedling-plus-exosome trial, conducted at eight renowned medspas across the country. The clinicians participated in the trial in order to analyze what is the most effective amount of RESILIÉLLE Age Zero ExosomeTM topical serum to be applied after facial microneedling. [Read more…]
The Booming Market for Exosomes in 2024
Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. [Read more…]
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
TORONTO and HAIFA, Israel — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 24
- Next Page »